Covalent inhibitors: a rational approach to drug discovery
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
In this review we provide a brief historic overview of covalent inhibitors and summarize recent advances focusing on developments in the last decade. Applications in challenging targets and future perspectives are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past 30 years, the rational design of covalent drugs has garnered increased interest, and covalently targeting non-conserved amino acids to increase selectivity has become commonplace2,5.”
From Advances in covalent drug discovery (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Covalent drugs also exhibit impressive performance in selective targeting,521 potentially providing novel inhibitory approaches for kinases such as CK1, which have previously only been targeted with non-covalent ATP competitive inhibitors.522”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [521]
The cited source says what the claim attributes to it.
In the citing paper
“Covalent inhibitors, which form covalent bonds with their target proteins, rely on the specificity and stability of these interactions to exhibit superior potency, selectivity, and duration of action. This mechanism offers patients a convenient therapeutic option.521,565”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [521]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
PENICILLIN-BINDING PROTEINS AND THE MECHANISM OF ACTION OF BETA-LACTAM ANTIBIOTICS
Waxman, D. J., & Strominger, J. L. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.004141 · Cited by 721
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620 · cited 1×
“In 2013, Walter et al.13 showed that a novel covalent inhibitor, CO-1686, inhibits a drug-resistance mutant of T790M EGFR.”
Background
Cited by
Items 201–300 of 403
Allosteric Covalent Inhibitors of the STAT3 Transcription Factor from Virtual Screening
Szalai, T. V., di Lorenzo, V., Péczka, N., Mihalovits, L. M., Petri, L., Ashraf, Q. F., de Araujo, E. D., Honti, V., Bajusz, D., & Keserű, G. M. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00622 · Cited by 6
Targeted Covalent Inhibitors for the Treatment of Malaria?
Kulkarni, S., Urbahns, K., & Spangenberg, T. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00684 · Cited by 6
Mirzaie, S., Abdi, F., GhavamiNejad, A., Lu, B., & Wu, X. Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-0267-2_11 · Cited by 6
Hariri, M., Darvish, F., Ndong, K.-P. M. M., Babouri, R., Babouri, R., Maguene, G. M., Burilov, A. R., Licznar‐Fajardo, P., Pirat, J., Ayad, T., et al. (2021) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2021.16.2.0252 · Cited by 6
Thiol Reactivity of N-Aryl α-Methylene-γ-lactams: Influence of the Guaianolide Structure
Dempe, D. P., Ji, C., Liu, P., & Brummond, K. M. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c01530 · Cited by 7
Krymov, S. K., Salnikova, D. I., Dezhenkova, L. G., Bogdanov, F. B., Korlyukov, A. A., Scherbakov, A. M., & Shchekotikhin, A. E. (2023) · Pharmaceuticals · doi:10.3390/ph17010032 · Cited by 7
“Pharmaceuticals 2024 , 17 , x FOR PEER REVIEW 2 of 20 Development of covalent inhibitors is one of the promising directions in drug discovery covalent inhibitors could have increased efficacy, selectivity, and duration of action of the drug on the target [7].”
Toward effective Atg8‐based ATTECs: Approaches and perspectives
Schwalm, M. P., Knapp, S., & Rogov, V. V. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30380 · Cited by 6
“17 In addition to conventional binders, covalent binders (reviewed in 33 – 35 ) may also serve as potential handles for ATTEC development.”
Free Energy Perturbation and Free-Energy Calculations Applied to Drug Design
Antunes, D., Santos, L. H., Guimarães, A. C. R., & Caffarena, E. R. (2024) · Computer-aided drug discovery and design · doi:10.1007/978-3-031-76718-0_10 · Cited by 8
Deep seeking covalent DNA encoded library for novel JAK3 inhibitor discovery
Chen, T., Cai, L., Dong, X., Zhang, L., Cheng, X., Qu, J., Yang, G., Gao, S., Luo, L., Ma, H., et al. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118448 · Cited by 5
Corrionero, A., Zhang, X., Alfonso, P., Morris, P. J., Klumpp-Thomas, C. A., Melani, C. J., McKnight, C. G., Phelan, J. D., Holland, D. O., Wilson, K. M., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00412 · Cited by 6
Allende, J., Olaizola, I., de Retana, A. M. O., Palácios, F., & Santos, J. M. D. L. (2024) · Molecules · doi:10.3390/molecules29051023 · Cited by 5
Cao, H., Huang, Z., Liu, Z., Zhang, X., Ren, Y., Hameed, M. S., Rao, L., Makunga, N. P., Dobrikov, G. M., & Wan, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01886 · Cited by 5
Rouch, C. C., Chatterjee, A. K., McCarty, C., Song, L., Chu, A., Johnson, K., Heacock, M. L., Riva, L., McNamara, C. W., Wolff, K. C., et al. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.130034 · Cited by 5
SERPINA1 is a new frontier in cancer immunotherapy and drug targeting by pan-cancer analysis
Fu, C. S., Miao, Y., Jiao, X., Fu, J., Liu, C., Yu, Z., & Wei, M. (2025) · Discover Oncology · doi:10.1007/s12672-025-02832-5 · Cited by 5
Macrocyclic Phage Display for Identification of Selective Protease Substrates
Faucher, F. F., Blažková, K., Lovell, S., Bertolini, M., Herrero-Bourdieu, J., Cosco, E. D., Bogyo, M. S., & Barniol‐Xicota, M. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04424 · Cited by 5
Xue, J., Li, M., Li, K., Wang, M., Yin, J., Sun, D., Deng, Y., Wei, Q., Wong, J., Zhu, T., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07765-z · Cited by 5
“OH) of target proteins through covalent bonds via mildly reactive electrophilic groups (warheads) [24].”
Computational and biophysical methods for the discovery and optimization of covalent drugs
Wang, G., Moitessier, N., & Mittermaier, A. (2023) · Chemical Communications · doi:10.1039/d3cc03285j · Cited by 8
Chi, F., Zhang, M., Han, Y., Shen, F., Peng, S., Su, B., Hou, Y., & Bai, G. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.109913 · Cited by 5
Zimmermann, T., Feng, J., de Campos, L. J., Knight, L. A., Schlötzer, J., Ramírez, Y. A., Schwickert, K., Zehe, M., Adler, T. B., Schirmeister, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00230 · Cited by 5
Arumugam, M., Pachamuthu, R. S., Rymbai, E., Jha, A. P., Rajagopal, K., Kothandan, R., Muthu, S., & Selvaraj, D. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10965-y · Cited by 6
“Due to this, the covalent inhibitors are found to exhibit toxicity because of their off-target reaction [43].”
Development of Low-Nanomolar Covalent Epoxide Inhibitors of Tubulin Detyrosinating Enzymes VASH1&2
Feral, A., Marcellin, G., Lannay, Y., Hennebert, C., Souf, Y., Talha, A., Haetty, A., Simon, M., Verdié, P., Louet, M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00980 · Cited by 5
Nochebuena, J., & Cisneros, G. A. (2022) · The Journal of Chemical Physics · doi:10.1063/5.0123698 · Cited by 5
Reactive Electrophiles and Metabolic Activation
Obach, R. S., & Kalgutkar, A. S. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00018-8 · Cited by 4
ARCaDia: single-round screening of a DNA-type targeted covalent binder possessing a latent warhead
Taki, M., Kuwahara, M., Li, C., Tomoda, N., Miyashita, N., Kan, T., & Yang, J. (2024) · Chemical Communications · doi:10.1039/d4cc04594g · Cited by 4
Covalent Inhibitors - An Overview of Design Process, Challenges and Future Directions
Mugisa, S., & Murahari, M. (2025) · Current Organic Chemistry · doi:10.2174/0113852728361926250123092017 · Cited by 5
Wang, Y., Luo, S., Sun, H., Huang, S., Shan, L., & Zhang, J.-F. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104347 · Cited by 4
Walker, J. C., Yan, K., & Derda, R. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00646 · Cited by 5
Covalent chemistry in targeted protein degradation
Tan, J., Liang, Y., Shao, S., & Shen, Y. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115777 · Cited by 4
Chemical Bonding in Homogenous Catalysis – Seen Through the Eyes of Vibrational Spectroscopy
Kraka, E., & Freindorf, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821978-2.00005-2 · Cited by 3
Exploring novel dilazep derivatives as hENT1 inhibitors and potentially covalent molecular tools
Dilweg, M. A., González, M. G., de Ruiter, M. D., Meijboom, N. J., van Veldhoven, J. P. D., Liu, R., Jespers, W., van Westen, G. J. P., Heitman, L. H., IJzerman, A. P., et al. (2024) · Purinergic Signalling · doi:10.1007/s11302-024-10026-x · Cited by 4
“Additionally, multiple covalent therapies are on the market showing advantages such as improved efficacy and decreased drug resistance [34].”
Design and testing of selective inactivators against an antifungal enzyme target
Friday, S. N., Cheng, D. W., Zagler, S. G., Zanella, B. S., Dietz, J. D., Calbat, C. N., Roach, L. T., Bagnal, C., Faile, I. S., Halkides, C. J., et al. (2021) · Drug Development Research · doi:10.1002/ddr.21875 · Cited by 4
“Several recent reviews have summarized the synthesis and testing of selective α-ketoamides and α,β-unsaturated carbonylcontaining inactivators (Ghosh et al., 2019; Sutanto et al., 2020).”
BackgroundTripathi, R. S., Anifowose, A., Lu, W., Yang, X., & Wang, B. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2116699 · Cited by 7
Corredor, J. D., Febres-Molina, C., Jaña, G. A., & Jiménez, V. A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01558 · Cited by 4
Huang, K., Chen, J., Hua, T.-Y., Chu, Y.-Y., Chiu, T.-Y., Liu, J.-Y., Tu, C.-I., Hsu, K., Kao, Y., Chu, J., et al. (2021) · JACS Au · doi:10.1021/jacsau.1c00420 · Cited by 4
Cherchi, F., Venturini, M., Magni, G., Scortichini, M., Jacobson, K. A., Pugliese, A. M., & Coppi, E. (2023) · Purinergic Signalling · doi:10.1007/s11302-023-09929-y · Cited by 5
“Irreversibly binding drugs containing a covalent warhead are now coming into focus in the pharmaceutical industry as a viable drug discovery approach [61].”
BackgroundHu, Q., Zhang, Y., Chen, P., Zhang, Y., Zhu, G., Liu, W., Wang, C., Zheng, S., Shen, N.-E., Wang, H., et al. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60577-7 · Cited by 7
Bajaj, T., Mosavati, B., Zhang, L. H., Parsa, M. S., Wang, H., Kerek, E. M., Liang, X., Dakhili, S. A. T., Wehri, E., Guo, S., et al. (2025) · RSC Advances · doi:10.1039/d4ra06955b · Cited by 3
Meehan, M. C., Scofield, G. E., Stahl, C. E., Wolfe, J. A., Horne, W. S., Liu, P., & Brummond, K. M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00833 · Cited by 3
An enzyme activity-based workflow for the identification and characterization of covalent inhibitors
Tang, B., Gladysheva, T. B., & Lang, P. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100250 · Cited by 3
State of the Art of IDH Inhibitors: Emerging Questions and Perspectives
de Lima, J. A. L., & Lima, L. M. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206382095250908095950 · Cited by 6
Discovery of a First‐in‐Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity
Qu, Z., Meke, F. N., Zhang, Z., Krabill, A. D., Muli, C. S., Jassim, B. A., Dong, J., Nguyen, Q. D., Bai, Y., Li, J., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202525126 · Cited by 8
Wu, Y., Chen, Y., 曹瑞恆, Li, X., & Zhang, X. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03241 · Cited by 5
Li, J., Zheng, M., Xu, Y., Yang, X., & Kang, J. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115398 · Cited by 3
Force, H. L., & Kraka, E. (2023) · Chemical Physics Letters · doi:10.1016/j.cplett.2023.140733 · Cited by 3
Natala, S. R., Habas, A., Stocking, E. M., Orry, A. J. W., Abagyan, R. A., Makale, M., & Wrasidlo, W. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130259 · Cited by 3
Hu, D., Zeng, H., Li, W., Zhang, Y., Chi, X., Liu, X., Zhang, H., Ge, G., Jiao, X., & Xie, P. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00563 · Cited by 3
Search for Specific Inhibitors Targeting Type IA Topoisomerases
Chadni, S. H., Ferdous, S., & Tse-Dinh, Y.-C. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169349 · Cited by 4
Enzyme Immobilization Technology to Treat Emerging Pollutants
Chauhan, P. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-41005-5_12 · Cited by 3
Jermusek, F. A., & Webb, L. J. (2023) · Biochemistry · doi:10.1021/acs.biochem.3c00366 · Cited by 4
Discovery of α-Amidobenzylboronates as Highly Potent Covalent Inhibitors of Plasma Kallikrein
Allison, M., Davie, R. L., Mogg, A. J., Hampton, S. L., Emsley, J., & Stocks, M. J. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00572 · Cited by 3
Dong, S., Huang, H. Y., Li, J., Li, X., Bunu, S. J., Yang, Y., Zhang, Y., Jia, Q., Xu, Z., Li, Y., et al. (2024) · Communications Chemistry · doi:10.1038/s42004-024-01279-z · Cited by 3
“As a result, covalent inhibitors are more ef fi cient, require lower dosages, less likely to cause drug resistance, and can easily target “ undruggable ” proteins 19,20 .”
(2023) · Biointerface Research in Applied Chemistry · doi:10.33263/briac135.460 · Cited by 4
Abadi, M. H. H. E., Bayani, F., & Sefidbakht, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-05375-5 · Cited by 5
Ai, Y., Xu, S., Zhang, Y., Liu, Z., & Liu, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03191 · Cited by 3
Sexton, M., Malachowski, W. P., Yap, G. P. A., Rachii, D., Feldman, G., Krasley, A. T., Chen, Z., Tran, M. A., Wiley, K., Matei, A., et al. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c02523 · Cited by 3
Mutate and Conjugate: A Method to Enable Rapid In-Cell Target Validation
Thomas, A., Serafini, M. T., Grant, E. K., Coombs, E. A. J., Bluck, J. P., Schiedel, M., McDonough, M. A., Reynolds, J. K., Lee, B., Platt, M. A., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00437 · Cited by 3
Franz, M., Mörchen, B., Degenhart, C., Gülden, D., Shkura, O., Wolters, D. A., Koch, U., Klebl, B., Stoll, R., Helfrich, I., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100167 · Cited by 4
Svenningsen, E. B., Ottosen, R. N., Jørgensen, K. B., Nišavić, M., Larsen, C. K., Hansen, B. K., Wang, Y., Lindorff‐Larsen, K., Tørring, T., Hacker, S. M., et al. (2022) · RSC Chemical Biology · doi:10.1039/d2cb00161f · Cited by 3
Srinivasan, B. (2023) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2023.08.004 · Cited by 3
Computational Insights into Acrylamide Fragment Inhibition of SARS-CoV-2 Main Protease
Chen, P., Wu, L., Qin, B., Yao, H., Xu, D., Cui, S., & Zhao, L. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46110765 · Cited by 2
“…of simulated data confirmed that these two acrylamide fragments align It is worth noting that there are already existing inhibitors and early fragment-based drug design studies in this domain, such as penicillin, omeprazole (a proton pump inhibitor), and acetylsalicylic acid (aspirin) [25,26].”
Wang, X., Lama, R., Kelleher, A. D., Rizzo, E., Galster, S. L., Xue, C., Zhang, Y., Wang, J., Qu, J., & Chemler, S. R. (2025) · Molecules · doi:10.3390/molecules30132696 · Cited by 4
“In fact, about 30% of the marketed drugs are covalent inhibitors including tamoxifen and other targeted therapies [29–31].”
Shuai, T., Zhang, R., Yuan, Z.-H., Zhang, M., Fan, Z., Ruan, X., Qi, Z., Xie, W., Liu, P., Uesugi, M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01365 · Cited by 4
Wang, H., Guo, Y.-M., Yang, J., Cao, C., Ren, J.-N., Ye, H.-Y.-X., & Chen, J. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01238 · Cited by 2
Kaneko, N., Himeno, M., Kobayashi, Y., Tanifuji, R., Kubota, H., Mizoguchi, H., Muroi, M., Suzuki, T., Sugiyama, M., Dohmae, N., et al. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00268k · Cited by 2
Patil, P., Ingenito, E., Fusco, R., Capriello, I., Guan, Z., Bhalkikar, A., Gibbons, J. G., Korba, T., Bashkyrtsev, S., Tkachenko, O., et al. (2025) · Green Chemistry · doi:10.1039/d5gc04440e · Cited by 2
Self-citationYe, S., Zhang, F., Zhao, J., Yang, Y., Zhu, Y., Yang, M., Zhang, Y., Zhao, D., Zhang, H., & Chen, J. (2025) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.5c08090 · Cited by 3
Direct Amidation of Tertiary N -Benzylamines
MacAllister, C. A., Jiang, Y., & Sather, A. C. (2026) · Organic Letters · doi:10.1021/acs.orglett.5c05384 · Cited by 2
Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer
Tan, Y., Zeng, C., Wang, J., & Ma, F. (2026) · Cancer Innovation · doi:10.1002/cai2.70043 · Cited by 6
“Owing to the relative bioorthogonality of these covalent warheads, other free covalent radioligands that do not bind to the target would experience rapid blood clearance without off‐target ligation, minimising the risk of toxicity [48, 59].”
Systematic Evaluation of Electrophile Reactivity and Stability for Covalent DNA‐Encoded Libraries
Puff, J., Assoni, G., Zhao, J., Zhang, Q., Ma, Z., Liu, H., Cui, W., Satz, A. L., Su, W., Kuai, L., et al. (2026) · Helvetica Chimica Acta · doi:10.1002/hlca.70064 · Cited by 2
Kinetic Analysis of Irreversible Covalent Enzyme Inhibitors and Its Use in Drug Design
Chaudière, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083383 · Cited by 2
USFDA‐Approved Small Molecules in the Year 2025: Medicinal Chemistry Strategies and Trends
Rao, M. P., Anwer, R., Benni, S. D., Babu, M. A., Singh, T., Ahmed, S., Fareed, M., & Bansal, N. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70272 · Cited by 2
“Overall, the approved anticancer drugs in 2025 suggest a rise in covalent inhibitors, the success of non‐kinase targets, and the targeting of protein–protein interactions and epigenetic pathways through structural biology‐driven drug design and development [44–46].”
Late-stage functionalization with strain-release warheads enables tunable covalent inhibition
Shultz, Z. P., Lee-Sam, A., Chang, Y., Sun, L., Grassie, D., Gabellini, A., Pedretty, K. P., Scattolin, T., Izumi, V., Fang, B., et al. (2026) · Science · doi:10.1126/science.adx7219 · Cited by 2
Bai, J., Guo, F., Li, M., Li, Y., & Lei, X. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00002k · Cited by 2
Thermal Stability and Utility of Dienes as Protecting Groups for Acrylamides
Hooper, A. R., & Burns, A. S. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00075 · Cited by 2
Reactivity Modulation of Reactive OFF–ON Type G-Quadruplex Alkylating Agents
Chen, Y., Onizuka, K., Hazemi, M. E., & Nagatsugi, F. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00458 · Cited by 2
Sherborne, G. J., Kemmitt, P. D., Prentice, C., Zysman‐Colman, E., Smith, A. D., & Fallan, C. (2022) · Angewandte Chemie · doi:10.1002/ange.202207829 · Cited by 2
Covalent Modifier Discovery Using Hydrogen/Deuterium Exchange–Mass Spectrometry
Kojima, H., Yanagi, R., Higuchi, E., Yoshizawa, M., Shimodaira, T., Kumagai, M., Kyoya, T., Sekine, M., Egawa, D., Ohashi, N., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01986 · Cited by 2
Drug development of covalent inhibitors
Dahal, U. P., & Wahlstrom, J. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00009-x · Cited by 2
Xu, W., Aikeremu, D., Wang, H., Li, J., & Li, H. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c00656 · Cited by 2
Covalency-enabled Drug Discovery is Redefining Druggability
McKenna, J. M., & Proctor, R. S. J. (2023) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2023.537 · Cited by 2
Qu, Z., Krabill, A. D., & Zhang, Z. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3569-8_19 · Cited by 5
Correlating Predicted Reactivities with Experimental Inhibition Data of Covalent ChlaDUB1 Inhibitors
Zimmermann, T., Endres, E., Sotriffer, C., & Decker, M. W. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00267 · Cited by 2
Xu, J., Chen, L., Wang, S., Zhang, W., Liang, J.-J., Lu, R., Deng, Z., & Zhou, Y. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c07955 · Cited by 2
Ramírez-Cortés, S. A., Durán-Vargas, A., Rauda-Ceja, J. A., Mendoza-Espinosa, P., Cofas‐Vargas, L. F., Cruz‐Rangel, A., Pérez‐Carreón, J. I., & García‐Hernández, E. (2025) · Biophysical Chemistry · doi:10.1016/j.bpc.2025.107410 · Cited by 3
Chakrabarti, A., Ganskow, C. S. G., Kagho, M. D., Jimidar, C. C., Wiese, L., Beyazıt, N., Beutling, U., Seeger, M., Smits, S., Nyström, S., et al. (2025) · ChemBioChem · doi:10.1002/cbic.202500152 · Cited by 3
Mohan, D., Venkatesan, R., Kandy, A. T., Muthu, S., Saravanan, J., Baskaran, R., Pethappachetty, P., & Selvaraj, D. (2025) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2025.104037 · Cited by 2
Catta‐Preta, C. M. C., Ramos, P. Z., Carnielli, J. B. T., Vasconcelos, S. N. S., Dowle, A., Fanti, R. C. D. O., dos Reis, C. V., Coelho, A. C., Massirer, K. B., Mottram, J. C., et al. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00610 · Cited by 2
“38 We used SV366 in tracer displacement assays to assess the cell permeability of WZ8040 and WZ3146 in Leishmania promastigotes.”
Lu, G., Ou, K., Jing, Y., Zhang, H., Feng, S., Yang, Z., Shen, G., Liu, J., Wu, C., & Wei, S. (2023) · Molecules · doi:10.3390/molecules28031435 · Cited by 2
“At the same time, covalent inhibitors are a double-edged sword: off-target toxicity may bring disastrous consequences [33].”
BackgroundPatel, D. V., Teli, D., Kanhed, A. M., Patel, N. R., Shah, B. S., Vora, A., Chhabria, M. T., & Yadav, M. R. (2020) · International Journal of Quantitative Structure-Property Relationships · doi:10.4018/ijqspr.20210401.oa1 · Cited by 2
“Covalent inhibitors hold an important place in the history of drug discovery, beginning in the late 19th century with aspirin and continuing with the current surge of rationally designed kinase inhibitors as anti-neoplastic agents (Sutanto et al., 2020).”
BackgroundInsights and Future Perspectives of Covalent Protein Degraders
Zhang, X. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch8 · Cited by 2
QM / MM for Structure‐Based Drug Design: Techniques and Applications
van der Kamp, M. W., & Begum, J. (2024) · Wiley eBooks · doi:10.1002/9783527840748.ch6 · Cited by 4
Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidates
Amberntsson, S., Foster, A. J., Chouhan, B., Wilkinson, S. D., Harlfinger, S., Smith, G., Kettle, J. G., Niedbala, M. J., Kavanagh, S. L., & Williams, D. P. (2025) · Toxicology Research · doi:10.1093/toxres/tfaf054 · Cited by 1
Froes, T. Q., Price, T. O. A., Godoi, B. F., Vaidergorn, M. D. M., dos Santos, T., Leite, P. I. P., Silva, D. G., da Purificação, A. D., Loch, L., Schenkman, S., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00462 · Cited by 1
The peptidomimetic approach for the design of viral protease inhibitors
Trabocchi, A. (2025) · The Enzymes · doi:10.1016/bs.enz.2025.06.007 · Cited by 1
Deciphering covalent kinase inhibitor binding landscape through structural kinome profiling
Zhao, Z., & Bourne, P. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118872 · Cited by 2
Discovery of a First‐in‐Class Covalent Allosteric SHP1 Inhibitor with Immunotherapeutic Activity
Qu, Z., Meke, F. N., Zhang, Z., Krabill, A. D., Muli, C. S., Jassim, B. A., Dong, J., Nguyen, Q. D., Bai, Y., Li, J., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202525126 · Cited by 1
Costa, M., Trischitta, P., Barnà, F. M., Sciortino, M. T., & Pennisi, R. (2026) · Pathogens · doi:10.3390/pathogens15020232 · Cited by 1
“This facilitates the formation of a covalent bond, leading to long-lasting enzyme inhibition, reduced dosing requirements, and enhanced selectivity, while requiring careful control of reactivity to prevent excessive off-target binding and undesirable side effects [30].”
Crafting Molecular Tools for 15‐Lipoxygenase‐1 in a Single Step
Louka, A., Spacho, N., Korovesis, D., Adamis, K. S., Papadopoulos, C., Kalaitzaki, E.-E., Tavernarakis, N., Neochoritis, C. G., & Eleftheriadis, N. (2024) · Angewandte Chemie · doi:10.1002/ange.202418291 · Cited by 1
Zhou, J., Tian, K., Li, Y., Li, J., Zhang, X., Ruan, C., Wang, Y., Qin, H., & Ye, M. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c00022 · Cited by 2
Metadata
- Authors
- Sutanto, F., Konstantinidou, M., & Dömling, A.
- Affiliations
- University of Groningen (NL)
- Corresponding author
- Dömling, Alexander
- Venue
- RSC Medicinal Chemistry
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 11
- Issue
- 8
- Pages
- 876-884
- ISSN
- 2632-8682 (ISSN-L)
- PMC
- PMC7557570
- OpenAlex
- W3038238188
- Cited by
- 389
- References
- 27
- Citations by year
- 2026: 50 · 2025: 75 · 2024: 72 · 2023: 64 · 2022: 75 · 2021: 48 · 2020: 5
- FWCI
- 19.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- RSC Medicinal Chemistry (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health (2R01GM097082-05)
- KWF Kankerbestrijding (10504)
- Lembaga Pengelola Dana Pendidikan
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- covalent inhibitors, drug discovery, off-target toxicity, cancer drug targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.